Neural Therapeutics receives conditional CSE approval for Hanf. com transaction

Neural Therapeutics Inc. has received conditional approval from the Canadian Securities Exchange (CSE) for the listing of its shares following a planned fundamental change transaction. The transaction involves CWE European Holdings Inc., the operator of the Hanf. com business in Germany.

Upon completion of the Series B transactions, Neural Therapeutics intends to change its corporate name to Hanf. com Inc. The company will acquire the remaining interest in CWE, making it a wholly-owned subsidiary of the resulting issuer.

The approval is subject to several conditions, including the completion of previously announced concurrent financing, the execution of escrow agreements, and necessary filings on SEDAR+. The CSE will determine the trading commencement date for the resulting issuer once all conditions are met.